MY131949A - Vaccines - Google Patents

Vaccines

Info

Publication number
MY131949A
MY131949A MYPI20023515A MYPI20023515A MY131949A MY 131949 A MY131949 A MY 131949A MY PI20023515 A MYPI20023515 A MY PI20023515A MY PI20023515 A MYPI20023515 A MY PI20023515A MY 131949 A MY131949 A MY 131949A
Authority
MY
Malaysia
Prior art keywords
fragment
epitope
hiv
gag
encodes
Prior art date
Application number
MYPI20023515A
Inventor
Andrew Beaton
Peter Franz Ertl
Gerald Wayne Gough
Andrew Lear
John Philip Tite
Catherine Ann Van Wely
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/004207 external-priority patent/WO2002024225A1/en
Priority claimed from GB0129604A external-priority patent/GB0129604D0/en
Priority claimed from GB0206462A external-priority patent/GB0206462D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY131949A publication Critical patent/MY131949A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

THE INVENTION PROVIDES A NUCLEOTIDE SEQUENCE THAT ENCODES AN HIV-1 GAG PROTEIN OR FRAGMENT THEREOF CONTAINING A GAG EPITOPE AND A SECOND HIV ANTIGEN OR A FRAGMENT ENCODING AN EPITOPE OF SAID SECOND HIV ANTIGEN, OPERABLY LINKED TO A HETEROLOGOUS PROMOTER. PREFERRED POLYNUCLEOTIDE SEQUENCES FURTHER ENCODES NEF OR A FRAGMENT THEREOF AND RT OR A FRAGMENT THEREOF.
MYPI20023515A 2001-09-20 2002-09-20 Vaccines MY131949A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination
GB0129604A GB0129604D0 (en) 2001-12-11 2001-12-11 Novel compounds
GB0206462A GB0206462D0 (en) 2002-03-19 2002-03-19 Vaccines

Publications (1)

Publication Number Publication Date
MY131949A true MY131949A (en) 2007-09-28

Family

ID=43927344

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20023515A MY131949A (en) 2001-09-20 2002-09-20 Vaccines

Country Status (7)

Country Link
KR (1) KR101067231B1 (en)
AT (1) ATE506439T1 (en)
DE (1) DE60239815D1 (en)
HK (1) HK1066830A1 (en)
MY (1) MY131949A (en)
TW (1) TWI329647B (en)
ZA (1) ZA200402189B (en)

Also Published As

Publication number Publication date
TWI329647B (en) 2010-09-01
ATE506439T1 (en) 2011-05-15
KR20040039387A (en) 2004-05-10
ZA200402189B (en) 2005-07-27
DE60239815D1 (en) 2011-06-01
HK1066830A1 (en) 2005-04-01
KR101067231B1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
WO2003025003A3 (en) Hiv-gag codon-optimised dna vaccines
MY145614A (en) Vaccine
BR0010361A (en) Genetic sequences of neisseria and use of these
AP2002002592A0 (en) Vaccine for the prophylactic or therapeutic immunization against HIV.
CY1106635T1 (en) N-FORMYL METHIONYL-PEPTIDE CONTAINING IMMUNOPRODUCT FOR VACCINES
MXPA05010007A (en) Improved alphavirus replicons and helper constructs.
SG152917A1 (en) Neisseria meningitidis antigens
SG156666A1 (en) Vaccines against japanese encephalitis virus and west nile virus
WO2000029561A3 (en) Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
DE69941049D1 (en) RETROVIRAL ADMINISTRATION SYSTEM
ZA200107072B (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV.
TW200502245A (en) Vaccine
MY131949A (en) Vaccines
IL156799A0 (en) Peptides having affinity for the gp120 viral protein and use thereof
DE69840326D1 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
MXPA02012593A (en) Bvdv virus-like particles.
DK1379273T3 (en) Nucleic acid adjuvants
WO2003052122A3 (en) Gp41 inhibitor
WO2003089571A3 (en) Ehrlichia canis genes and vaccines
WO2002022663A3 (en) Stress resistant retroviruses
DK1578772T3 (en) Cytokines and cytokine receptors with reduced immunogenicity
HUP0500099A2 (en) Glucuronyl c5-epimerase, dna encoding the same and uses thereof
ATE414905T1 (en) DIABETES MODEL
AUPP700798A0 (en) Recombinant viral constructs and methods relating thereto
MX2023003651A (en) Attenuated porcine epidemic diarrhea virus.